Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148899 · ClinicalTrials.gov registry record · Phase 2
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
A Phase 2 study, sponsored by George Washington University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03148899: Completed Phase 2 study, sponsored by George Washington University.
NCT03148899 is a Phase 2 study that has completed, run by George Washington University. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03148899, a Phase 2 study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current literature and new basic science results detailed above on the role of oxytocin in cardiovascular control, will test if oxytocin administration improves adverse cardiovascular events during the recurrent nocturnal apneas in patients with OSA. This project will lay the groundwork and provide preliminary data to obtain NIH funding to test this important hypotheses more thoroughly and in larger clinical trials. This study will explore if intranasal oxytocin has any positive cardiovascular benefits in patients with sleep apnea.
Interventions
- DRUG Oxytocin Intranasal Spray
- DRUG Placebo Intranasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-07-27 |
| Est. Completion | 2020-06-07 |
| Phase | Phase 2 |
What the finished NCT03148899 record still lists
NCT03148899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxytocin Intranasal Spray is the first listed.
NCT03148899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03148899 about?
NCT03148899 is a clinical study titled "Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep". In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current liter...
What is the current status of trial NCT03148899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-07-27. Estimated completion is 2020-06-07.
What interventions are being tested in trial NCT03148899?
The interventions under investigation include: Oxytocin Intranasal Spray (DRUG), Placebo Intranasal Spray (DRUG).
Who is sponsoring clinical trial NCT03148899?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03148899's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI